Deciphera Pharmaceuticals’ (NASDAQ:DCPH) quiet period is set to end on Tuesday, November 7th. Deciphera Pharmaceuticals had issued 7,500,000 shares in its public offering on September 28th. The total size of the offering was $127,500,000 based on an initial share price of $17.00. During Deciphera Pharmaceuticals’ quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

A number of research analysts have recently weighed in on the company. Instinet assumed coverage on Deciphera Pharmaceuticals in a research report on Monday, October 23rd. They set a “buy” rating and a $57.00 price objective on the stock. J P Morgan Chase & Co assumed coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued an “overweight” rating and a $30.00 price target on the stock. Nomura assumed coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued a “buy” rating and a $57.00 price target on the stock. JMP Securities assumed coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued an “outperform” rating and a $38.00 price target on the stock. Finally, Piper Jaffray Companies assumed coverage on Deciphera Pharmaceuticals in a report on Monday, October 23rd. They issued an “overweight” rating and a $35.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus price target of $43.40.

TRADEMARK VIOLATION NOTICE: “Deciphera Pharmaceuticals, Inc.’s Quiet Period To End on November 7th (NASDAQ:DCPH)” was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://theolympiareport.com/2017/11/02/deciphera-pharmaceuticals-inc-s-quiet-period-to-end-on-november-7th-nasdaqdcph.html.

In other Deciphera Pharmaceuticals news, major shareholder New Leaf Venture Management Ii purchased 375,000 shares of the stock in a transaction on Monday, October 2nd. The shares were bought at an average price of $17.00 per share, for a total transaction of $6,375,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

A number of hedge funds have recently modified their holdings of DCPH. Emerald Advisers Inc. PA purchased a new position in Deciphera Pharmaceuticals during the third quarter worth approximately $6,661,000. Emerald Mutual Fund Advisers Trust purchased a new position in Deciphera Pharmaceuticals during the third quarter worth approximately $5,548,000. Finally, Kornitzer Capital Management Inc. KS purchased a new position in Deciphera Pharmaceuticals during the third quarter worth approximately $2,172,000.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases.

Receive News & Ratings for Deciphera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.